Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130


The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.

Liu KS, Ding WC, Wang SX, Liu Z, Xing GW, Wang Y, Wang YF.

Oncol Rep. 2012 Jun;27(6):1904-10. doi: 10.3892/or.2012.1738. Epub 2012 Mar 22.


SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.

Wang SX, Ju HQ, Liu KS, Zhang JX, Wang X, Xiang YF, Wang R, Liu JY, Liu QY, Xia M, Xing GW, Liu Z, Wang YF.

Biosci Biotechnol Biochem. 2011;75(8):1540-5. Epub 2011 Aug 7.


The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.

Wang R, Shao F, Liu Z, Zhang J, Wang S, Liu J, Liu H, Chen H, Liu K, Xia M, Wang Y.

Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.


Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Clin Cancer Res. 2011 Jan 1;17(1):122-33. doi: 10.1158/1078-0432.CCR-10-0253.


SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC.

Blood. 2009 Jan 22;113(4):846-55. doi: 10.1182/blood-2008-04-151928. Epub 2008 Oct 23.


SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB.

Clin Cancer Res. 2008 Jan 1;14(1):240-8. doi: 10.1158/1078-0432.CCR-07-1667.


Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines.

Chinn DC, Holland WS, Yoon JM, Zwerdling T, Mack PC.

Pediatr Blood Cancer. 2012 Jun;58(6):885-90. doi: 10.1002/pbc.23270. Epub 2011 Jul 27.


Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells.

Wang X, Wang S, Liu Y, Huang D, Zheng K, Zhang Y, Wang X, Liu Q, Yang D, Wang Y.

Oncol Rep. 2015 Jan;33(1):230-8. doi: 10.3892/or.2014.3552. Epub 2014 Oct 20.


Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.

Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ.

Clin Cancer Res. 2011 Aug 15;17(16):5432-42. doi: 10.1158/1078-0432.CCR-11-0592. Epub 2011 Jun 29. Retraction in: Clin Cancer Res. 2017 Jan 15;23 (2):612.


SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells.

Liu KS, Liu H, Qi JH, Liu QY, Liu Z, Xia M, Xing GW, Wang SX, Wang YF.

Cancer Lett. 2012 May 28;318(2):180-8. doi: 10.1016/j.canlet.2011.12.015. Epub 2011 Dec 17.


The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress.

Wang X, Wang S, Liu Y, Ding W, Zheng K, Xiang Y, Liu K, Wang D, Zeng Y, Xia M, Yang D, Wang Y.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):160-6. doi: 10.1016/j.bbrc.2014.02.081. Epub 2014 Feb 25.


The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo.

Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X, Wang R, Di J, Li T, Wang W, Wu X.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1321-8. doi: 10.1007/s00432-012-1201-7. Epub 2012 Apr 6.


Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells.

Liu Y, Wang X, Wang Y, Zhang Y, Zheng K, Yan H, Zhang L, Chen W, Wang X, Liu Q, Wang S, Wang Y.

Int J Oncol. 2015 Jan;46(1):299-307. doi: 10.3892/ijo.2014.2714. Epub 2014 Oct 20.


A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A.

Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4916.


SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.

Wang J, Yang Z, Wen J, Ma F, Wang F, Yu K, Tang M, Wu W, Dong Y, Cheng X, Nie C, Chen L.

J Pharmacol Sci. 2014;126(3):198-207. Epub 2014 Oct 21.


Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death.

Bai L, Xu S, Chen W, Li Z, Wang X, Tang H, Lin Y.

Apoptosis. 2011 Jan;16(1):45-54. doi: 10.1007/s10495-010-0542-4.


The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS.

Clin Cancer Res. 2012 May 1;18(9):2502-14. doi: 10.1158/1078-0432.CCR-11-2612. Epub 2012 Feb 20.


BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ.

Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758.


Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth.

Lin P, Yi Y, Lu M, Wang M, Yang Y, Lu Y, Song S, Zheng Z, Deng X, Zhang L.

Anticancer Drugs. 2015 Jan;26(1):25-34. doi: 10.1097/CAD.0000000000000135.


Supplemental Content

Support Center